Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

Détails

ID Serval
serval:BIB_30E212DC7690
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.
Périodique
Atherosclerosis
Auteur(s)
Weissler E.H., Jones W.S., Desormais I., Debus S., Mazzolai L., Espinola-Klein C., Nikol S., Nehler M., Sillesen H., Aboyans V., Patel M.R.
ISSN
1879-1484 (Electronic)
ISSN-L
0021-9150
Statut éditorial
Publié
Date de publication
06/11/2020
Peer-reviewed
Oui
Volume
315
Pages
10-17
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: aheadofprint
Résumé
Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD.
MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with coronary artery disease or lower extremity peripheral artery disease.
Thirteen trials were included ranging in size from 7243 to 27,395 patients. In 9 trials (CHARISMA, TRA 2°P-TIMI 50, PEGASUS-TIMI 54, VOYAGER PAD, TRACER, EUCLID, TRILOGY ACS, PLATO, and COMPASS), patients in the PVD subgroup treated with increased-intensity antithrombotic therapy had similar or greater relative risk reductions for ischemic events in comparison with the general trial cohorts. In four trials (DAPT, THEMIS, APPRAISE-2, and ATLAS ACS 2 TIMI 51), the PVD subgroup had an increased hazard of ischemic events with increased-intensity therapy compared with the general trial cohorts.
More intense antithrombotic therapy in patients with PVD was associated with a similar relative risk reduction for ischemic events compared with patients without PVD. Therefore, patients with PVD benefit from a larger absolute risk reduction because of their higher baseline risk. Future trials in patients with atherosclerotic cardiovascular disease should intentionally include PVD patients to adequately assess treatment options for this under-studied, under-treated population.
Mots-clé
Coronary artery disease, Lower extremity peripheral artery disease, Polyvascular disease
Pubmed
Création de la notice
23/11/2020 14:33
Dernière modification de la notice
18/02/2021 6:29
Données d'usage